584 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Itau Unibanco Holding S.A.

Itau Unibanco Holding S.A. bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 584 shares of the life sciences company’s stock, valued at approximately $61,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Gryphon Financial Partners LLC increased its holdings in Illumina by 22.1% during the 4th quarter. Gryphon Financial Partners LLC now owns 1,807 shares of the life sciences company’s stock worth $252,000 after acquiring an additional 327 shares during the period. Cambridge Investment Research Advisors Inc. grew its position in shares of Illumina by 134.1% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 17,316 shares of the life sciences company’s stock valued at $2,411,000 after purchasing an additional 9,918 shares in the last quarter. Commerce Bank increased its holdings in shares of Illumina by 14.7% in the fourth quarter. Commerce Bank now owns 10,454 shares of the life sciences company’s stock worth $1,456,000 after purchasing an additional 1,339 shares during the period. Nomura Asset Management Co. Ltd. raised its position in shares of Illumina by 0.3% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 53,859 shares of the life sciences company’s stock worth $7,499,000 after buying an additional 187 shares in the last quarter. Finally, Evermay Wealth Management LLC boosted its stake in Illumina by 426.5% during the fourth quarter. Evermay Wealth Management LLC now owns 1,074 shares of the life sciences company’s stock valued at $150,000 after buying an additional 870 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Down 2.4 %

Shares of NASDAQ ILMN opened at $131.20 on Monday. The company has a market cap of $20.90 billion, a price-to-earnings ratio of -16.10 and a beta of 1.15. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 1.04. The firm’s fifty day moving average is $125.25 and its 200 day moving average is $120.47. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $148.19.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 EPS for the quarter, beating the consensus estimate of $0.12 by $0.24. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the firm posted $0.32 earnings per share. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post 3.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ILMN shares. Evercore ISI lowered their price target on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a report on Tuesday, June 11th. Stephens reaffirmed an “overweight” rating and issued a $170.00 target price on shares of Illumina in a research note on Wednesday, July 10th. Robert W. Baird increased their price target on shares of Illumina from $119.00 to $124.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $242.00 target price on shares of Illumina in a research report on Wednesday, August 14th. Finally, Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $151.05.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.